Viemed Healthcare Inc (VMD)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $347.48M
Last updated: Nov 17, 2026 at 11:04 AM ET
Viemed Healthcare Inc (VMD) Earnings: Report Dates and Results
Viemed Healthcare (VMD) is expected to report earnings on Mar 2, 2027. In the quarter ended Sep 30, 2026, Viemed Healthcare reported EPS of $0.11, below the $0.12 estimate. It beat the EPS estimate in 2 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
VMD has an expected report date of Mar 2, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 14.3% above the $0.14 reported for the quarter ended Dec 31, 2025.
VMD Earnings Call
The latest VMD earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 33 quarters below that had an estimate, VMD beat 11, missed 16 and matched 6. Revenue for the quarter ended Sep 30, 2026 was $80.67M, up 12.2% from $71.91M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.11 | $0.12 | $0.11 - $0.13 | -8.33% | Miss | +22.2% | 3 | 0 up, 0 down | Nov 4, 2026 | $80.67M |
| Jun 30, 2026 | $0.07 | $0.10 | $0.10 - $0.10 | -30.00% | Miss | -12.5% | 1 | 1 up, 1 down | Aug 3, 2026 | $78.10M |
| Mar 31, 2026 | $0.06 | $0.09 | $0.09 - $0.09 | -33.33% | Miss | 0.0% | 2 | 0 up, 0 down | May 5, 2026 | $75.41M |
| Dec 31, 2025 | $0.14 | $0.13 | $0.12 - $0.13 | +7.69% | Beat | +34.5% | 2 | 1 up, 0 down | Mar 4, 2026 | $76.18M |
| Sep 30, 2025 | $0.09 | $0.09 | $0.09 - $0.10 | 0.00% | In line | -10.0% | 2 | 0 up, 1 down | Nov 5, 2025 | $71.91M |
| Jun 30, 2025 | $0.08 | $0.09 | N/A | -11.11% | Miss | 0.0% | N/A | 0 up, 0 down | Aug 6, 2025 | $63.06M |
| Mar 31, 2025 | $0.06 | $0.06 | N/A | 0.00% | In line | +50.0% | N/A | 0 up, 0 down | May 7, 2025 | $59.13M |
| Dec 31, 2024 | $0.10 | $0.10 | $0.10 - $0.10 | +4.10% | Beat | +15.7% | 1 | 0 up, 1 down | Mar 10, 2025 | $60.70M |
| Sep 30, 2024 | $0.10 | $0.06 | $0.06 - $0.09 | +66.67% | Beat | +25.0% | 2 | 0 up, 0 down | Nov 6, 2024 | $58.00M |
| Jun 30, 2024 | $0.08 | $0.07 | $0.07 - $0.07 | +14.29% | Beat | +33.3% | 1 | 0 up, 0 down | Aug 7, 2024 | $54.97M |
| Mar 31, 2024 | $0.04 | $0.07 | $0.07 - $0.07 | -42.86% | Miss | 0.0% | 1 | 0 up, 0 down | May 6, 2024 | $50.59M |
| Dec 31, 2023 | $0.09 | $0.10 | $0.10 - $0.10 | -10.00% | Miss | +50.0% | 1 | 0 up, 0 down | Mar 6, 2024 | $50.74M |
| Sep 30, 2023 | $0.08 | $0.09 | $0.08 - $0.09 | -11.11% | Miss | +166.7% | 2 | 0 up, 0 down | Nov 1, 2023 | $49.40M |
| Jun 30, 2023 | $0.06 | $0.04 | $0.04 - $0.06 | +50.00% | Beat | +200.0% | 2 | 0 up, 0 down | Aug 9, 2023 | $43.31M |
| Mar 31, 2023 | $0.04 | $0.04 | N/A | 0.00% | In line | 0.0% | 1 | 0 up, 0 down | May 8, 2023 | $39.56M |
| Dec 31, 2022 | $0.06 | $0.04 | N/A | +50.00% | Beat | -40.0% | 1 | 0 up, 0 down | Mar 2, 2023 | $37.51M |
| Sep 30, 2022 | $0.03 | $0.04 | $0.04 - $0.05 | -25.00% | Miss | -25.0% | 2 | 0 up, 0 down | Nov 1, 2022 | $35.76M |
| Jun 30, 2022 | $0.02 | $0.05 | N/A | -60.00% | Miss | -50.0% | 1 | 0 up, 0 down | Aug 2, 2022 | $33.31M |
| Mar 31, 2022 | $0.04 | $0.06 | N/A | -33.33% | Miss | 0.0% | 1 | 0 up, 0 down | May 3, 2022 | $32.26M |
| Dec 31, 2021 | $0.10 | $0.06 | N/A | +66.67% | Beat | -16.7% | N/A | N/A | Mar 7, 2022 | $31.96M |
| Sep 30, 2021 | $0.04 | $0.04 | N/A | 0.00% | In line | -42.9% | N/A | N/A | Nov 1, 2021 | $29.29M |
| Jun 30, 2021 | $0.04 | $0.03 | N/A | +33.33% | Beat | -91.7% | N/A | N/A | Aug 2, 2021 | $27.40M |
| Mar 31, 2021 | $0.04 | $0.05 | N/A | -20.00% | Miss | -63.6% | N/A | N/A | May 3, 2021 | $28.42M |
| Dec 31, 2020 | $0.12 | $0.03 | N/A | +300.00% | Beat | +100.0% | N/A | N/A | Mar 3, 2021 | $31.20M |
| Sep 30, 2020 | $0.07 | $0.09 | N/A | -22.22% | Miss | 0.0% | N/A | N/A | Nov 4, 2020 | $33.45M |
| Jun 30, 2020 | $0.48 | $0.26 | N/A | +84.62% | Beat | +860.0% | N/A | N/A | Aug 5, 2020 | $42.85M |
| Mar 31, 2020 | $0.11 | $0.08 | N/A | +37.50% | Beat | +120.0% | N/A | N/A | May 4, 2020 | $23.81M |
| Dec 31, 2019 | $0.06 | $0.07 | N/A | -14.29% | Miss | +20.0% | N/A | N/A | Mar 3, 2020 | $21.45M |
| Sep 30, 2019 | $0.07 | $0.07 | N/A | 0.00% | In line | +16.7% | N/A | N/A | Nov 4, 2019 | $20.37M |
| Jun 30, 2019 | $0.05 | $0.06 | N/A | -16.67% | Miss | -16.7% | N/A | N/A | Aug 9, 2019 | $20.32M |
| Mar 31, 2019 | $0.05 | $0.08 | N/A | -37.50% | Miss | -16.7% | N/A | N/A | May 6, 2019 | $18.11M |
| Dec 31, 2018 | $0.05 | $0.08 | N/A | -37.50% | Miss | N/A | N/A | N/A | Feb 27, 2019 | $18.49M |
| Sep 30, 2018 | $0.06 | $0.06 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 5, 2018 | $17.16M |
| Jun 30, 2018 | $0.06 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 13, 2018 | $15.51M |
| Mar 31, 2018 | $0.06 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 7, 2018 | $14.11M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.37, up 14.2% from the year before. It was $0.23 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.37 | +14.2% |
| Dec 31, 2024 | $0.32 | +20.0% |
| Dec 31, 2023 | $0.27 | +80.0% |
| Dec 31, 2022 | $0.15 | -31.8% |
| Dec 31, 2021 | $0.22 | -71.8% |
| Dec 31, 2020 | $0.78 | +239.1% |
| Dec 31, 2019 | $0.23 | N/A |
| Dec 31, 2018 | $0.23 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,000 words across 8 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,040 | 8 | |
| 2026Q2 | Jun 30, 2026 | 3,831 | 6 | |
| 2026Q1 | Mar 31, 2026 | 4,455 | 5 | |
| 2025Q4 | Dec 31, 2025 | 4,586 | 7 | |
| 2025Q3 | Sep 30, 2025 | 4,428 | 7 | |
| 2025Q2 | Jun 30, 2025 | 3,530 | 6 | |
| 2025Q1 | Mar 31, 2025 | 4,943 | 7 | |
| 2024Q4 | Dec 31, 2024 | 5,093 | 6 |
2026Q3 Earnings Call
Opening remarks
Trae Paul Fitzgerald CFO Thank you, and good morning, everyone. Please note that our remarks in this conference call may include forward-looking statements under the U.S. Federal Securities Laws or forward-looking information under applicable Canadian securities legislation, which we collectively refer to as forward-looking statements. Such statements reflect the company's current views and intentions with respect to future results or events and are subject to certain risks and uncertainties, which could cause actual results or events to vary from those indicated in forward-looking statements. Examples of such risks and uncertainties are discussed in our disclosure documents filed with the SEC or the securities regulatory authorities in certain provinces of Canada. Because of these risks and uncertainties, investors should not place undue reliance on forward-looking statements. Forward-looking statements made in this conference call are made as of today, and the company undertakes no obligations to update or revise any forward-looking statements except as required by law. The third-quarter financial supplement and financial news release, as well as the related financial statements, are available on the SEC's website. With that, I will turn the call over to our Chief Executive Officer, Casey Hoyt.
Casey Hoyt CEO Thank you, Trae. Good morning, everyone, and thank you for joining us. Before getting into the results, I want to thank our roughly 1,500 employees. Their daily work with patients and referral partners is what makes our growth possible. I appreciate the care they provide and the work they put into serving more patients as Viemed continues to grow. The third quarter was another strong quarter for Viemed, with record revenue of $80.7 million, representing 12.2% growth over last year. Just as importantly, that growth translated into stronger earnings. Net income attributable to Viemed increased 32% year over year and approximately 68% from the second quarter. We are continuing to grow the business at a double-digit pace, demonstrating the earnings potential of the platform we have built. For the first time since the Lehan acquisition, both the current- and prior-year quarters include a full three months of Lehan's operations. That gives us a much clearer picture of our growth, with a 12.2% increase reflecting expansion across our existing businesses rather than the incremental revenue contribution of an acquisition. Sleep therapy was a particular source of strength this quarter, and we are also seeing encouraging results from bringing maternal health services into our established Viemed markets. The success of those initial maternal health markets gives us confidence to broaden the rollout. We are now on track to enter two additional states per quarter beginning in the fourth quarter, establishing a regular pace of expansion. The markets we have already entered are still early in their development.
Frequently Asked Questions About VMD
When is Viemed Healthcare's next earnings date?
Viemed Healthcare's next earnings report is expected for Mar 2, 2027.
Did VMD beat earnings estimates last quarter?
No. Viemed Healthcare reported EPS of $0.11 for the quarter ended Sep 30, 2026, below the $0.12 estimate by 8.33%.
What EPS do analysts expect from VMD next quarter?
The consensus EPS estimate for Viemed Healthcare for the quarter ending Dec 31, 2026 is $0.16 from 4 analysts, with estimates from $0.15 to $0.18.
How often does VMD beat earnings estimates?
Viemed Healthcare beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -8.87%.
VMD pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors